Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?

Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of pati...

Descripción completa

Detalles Bibliográficos
Autores: Mahé, Isabelle|||0000-0003-1760-7880, Sterpu, Raluca, Bertoletti, Laurent, López-Jiménez, Luciano, Mellado Joan, Meritxell, Trujillo-Santos, Javier|||0000-0003-0861-9927, Ballaz, Aitor, Hernández Blasco, Luis Manuel, Marchena, Pablo Javier, Monreal Bosch, Manuel
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:162163
Acceso en línea:https://ddd.uab.cat/record/162163
https://dx.doi.org/urn:doi:10.1371/journal.pone.0128741
Access Level:acceso abierto
Palabra clave:Venous thromboembolism
Anticoagulant therapy
Cancer treatment
Deep vein thrombosis
Hemorrhage
Anemia
Heparin
Renal cancer
Descripción
Sumario:Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of patients with VTE) to report the use of long-term anticoagulant therapy over time and to identify predictors of anticoagulant choice (regarding international guidelines) in patients with- and without cancer. Among 35,280 patients without cancer, 82% received long-term VKA (but 17% started after the first week). Among 4,378 patients with cancer, 66% received long term LMWH as monotherapy. In patients without cancer, recent bleeding (odds ratio [OR] 2.70, 95% CI 2.26-3.23), age >70 years (OR 1.15, 95% CI 1.06-1.24), immobility (OR 2.06, 95% CI 1.93-2.19), renal insufficiency (OR 2.42, 95% CI 2.15-2.71) and anemia (OR 1.75, 95% CI 1.65-1.87) predicted poor adherence to guidelines. In those with cancer, anemia (OR 1.83, 95% CI 1.64-2.06), immobility (OR 1.51, 95% CI 1.30-1.76) and metastases (OR 3.22, 95% CI 2.87-3.61) predicted long-term LMWH therapy. In conclusion, we report practices of VTE therapy in real life and found that a significant proportion of patients did not receive the recommended treatment. The perceived increased risk for bleeding has an impact on anticoagulant treatment decision.

Similares en LA Referencia